Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K-ATP channel components

AJ Ball, Janie McCluskey, Peter Flatt, Neville McClenaghan

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Clonal insulin-secreting BRIN-BD11 cells were used to examine effects of chronic 72-144 h exposure to the sulphonylureas tolbutamide and glibenclamide on insulin release, cellular insulin content, and mRNA levels of the Kir6.2 and SUR1 subunits of the beta-cell K-ATP channel. Chronic exposure for 72-144 It to 5-100 muM tolbutamide and glibenclamide resulted in a time- and concentration-dependent irreversible decline in sulphonylurea-induced insulin secretion. In contrast, the decline in cellular insulin content induced by chronic exposure to high concentrations of sulphonylureas was readily reversible. Chronic exposure to tolbutamide or glibenclamide had no effect upon transcription of the Kir6.2 or SUR1 subunits of the pancreatic beta-cell K-ATP channel. Whilst further studies are required to understand the precise nature of the chronic interactions of sulphonylurea with the insulin exocytotic mechanism, these observations may partially explain the well-known progressive failure of sulphonylurea therapy in type 2 diabetes. (C) 2003 Elsevier Ltd. All rights reserved.
LanguageEnglish
Pages41-46
JournalPharmacological Research
Volume50
Issue number1
DOIs
Publication statusPublished - Jul 2004

Fingerprint

Tolbutamide
Glyburide
Adenosine Triphosphate
Insulin
Insulin-Secreting Cells
Type 2 Diabetes Mellitus
Messenger RNA

Cite this

@article{a67d917e401645eb939a352643d43433,
title = "Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K-ATP channel components",
abstract = "Clonal insulin-secreting BRIN-BD11 cells were used to examine effects of chronic 72-144 h exposure to the sulphonylureas tolbutamide and glibenclamide on insulin release, cellular insulin content, and mRNA levels of the Kir6.2 and SUR1 subunits of the beta-cell K-ATP channel. Chronic exposure for 72-144 It to 5-100 muM tolbutamide and glibenclamide resulted in a time- and concentration-dependent irreversible decline in sulphonylurea-induced insulin secretion. In contrast, the decline in cellular insulin content induced by chronic exposure to high concentrations of sulphonylureas was readily reversible. Chronic exposure to tolbutamide or glibenclamide had no effect upon transcription of the Kir6.2 or SUR1 subunits of the pancreatic beta-cell K-ATP channel. Whilst further studies are required to understand the precise nature of the chronic interactions of sulphonylurea with the insulin exocytotic mechanism, these observations may partially explain the well-known progressive failure of sulphonylurea therapy in type 2 diabetes. (C) 2003 Elsevier Ltd. All rights reserved.",
author = "AJ Ball and Janie McCluskey and Peter Flatt and Neville McClenaghan",
year = "2004",
month = "7",
doi = "10.1016/j.phrs.2003.12.001",
language = "English",
volume = "50",
pages = "41--46",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Elsevier",
number = "1",

}

Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K-ATP channel components. / Ball, AJ; McCluskey, Janie; Flatt, Peter; McClenaghan, Neville.

In: Pharmacological Research, Vol. 50, No. 1, 07.2004, p. 41-46.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K-ATP channel components

AU - Ball, AJ

AU - McCluskey, Janie

AU - Flatt, Peter

AU - McClenaghan, Neville

PY - 2004/7

Y1 - 2004/7

N2 - Clonal insulin-secreting BRIN-BD11 cells were used to examine effects of chronic 72-144 h exposure to the sulphonylureas tolbutamide and glibenclamide on insulin release, cellular insulin content, and mRNA levels of the Kir6.2 and SUR1 subunits of the beta-cell K-ATP channel. Chronic exposure for 72-144 It to 5-100 muM tolbutamide and glibenclamide resulted in a time- and concentration-dependent irreversible decline in sulphonylurea-induced insulin secretion. In contrast, the decline in cellular insulin content induced by chronic exposure to high concentrations of sulphonylureas was readily reversible. Chronic exposure to tolbutamide or glibenclamide had no effect upon transcription of the Kir6.2 or SUR1 subunits of the pancreatic beta-cell K-ATP channel. Whilst further studies are required to understand the precise nature of the chronic interactions of sulphonylurea with the insulin exocytotic mechanism, these observations may partially explain the well-known progressive failure of sulphonylurea therapy in type 2 diabetes. (C) 2003 Elsevier Ltd. All rights reserved.

AB - Clonal insulin-secreting BRIN-BD11 cells were used to examine effects of chronic 72-144 h exposure to the sulphonylureas tolbutamide and glibenclamide on insulin release, cellular insulin content, and mRNA levels of the Kir6.2 and SUR1 subunits of the beta-cell K-ATP channel. Chronic exposure for 72-144 It to 5-100 muM tolbutamide and glibenclamide resulted in a time- and concentration-dependent irreversible decline in sulphonylurea-induced insulin secretion. In contrast, the decline in cellular insulin content induced by chronic exposure to high concentrations of sulphonylureas was readily reversible. Chronic exposure to tolbutamide or glibenclamide had no effect upon transcription of the Kir6.2 or SUR1 subunits of the pancreatic beta-cell K-ATP channel. Whilst further studies are required to understand the precise nature of the chronic interactions of sulphonylurea with the insulin exocytotic mechanism, these observations may partially explain the well-known progressive failure of sulphonylurea therapy in type 2 diabetes. (C) 2003 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.phrs.2003.12.001

DO - 10.1016/j.phrs.2003.12.001

M3 - Article

VL - 50

SP - 41

EP - 46

JO - Pharmacological Research

T2 - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 1

ER -